{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:38:16Z","timestamp":1791005896207,"version":"4.1.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immunotherapy begins to be widely used due to the increasing exploration and gratifying effects in multiple cancers. Chordoma, as a rare bone malignant tumor, often recurs and metastasizes after undergoing surgery and radiotherapy. Therefore, immunotherapy can be explored as an emerging, potentially effective treatment to improve the survival rate and clinical benefit of patients. However, a variety of immune-related adverse events (irAEs) cannot be avoided completely. And the immunotherapy-induced myocarditis, as a rare but fatal irAE, has been increasingly reported. Understanding the mechanism involved in irAEs can inform best practices for side effects management. Here, we firstly reported a case of immune myocarditis and subsequent myasthenia gravis (MG) following anti-PD-1 treatment for chordoma.<\/jats:p>","DOI":"10.3389\/fimmu.2021.682262","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T09:30:31Z","timestamp":1625736631000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Immune Myocarditis Overlapping With Myasthenia Gravis Due to Anti-PD-1 Treatment for a Chordoma Patient: A Case Report and Literature Review"],"prefix":"10.3389","volume":"12","author":[{"given":"Shujing","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenrong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.75.1743","article-title":"Osteosarcoma, Chondrosarcoma, and Chordoma","volume":"36","author":"Whelan","year":"2018","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx054","article-title":"Best Practices for the Management of Local-Regional Recurrent Chordoma: A Position Paper by the Chordoma Global Consensus Group","volume":"28","author":"Stacchiotti","year":"2017","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)71190-8","article-title":"Building a Global Consensus Approach to Chordoma: A Position Paper From the Medical and Patient Community","volume":"16","author":"Stacchiotti","year":"2015","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41591-018-0312-3","article-title":"Small-Molecule Targeting of Brachyury Transcription Factor Addiction in Chordoma","volume":"25","author":"Sharifnia","year":"2019","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/s0140-6736(18)30533-6","article-title":"Increased Reporting of Fatal Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1903064","article-title":"Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy","volume":"380","author":"Esfahani","year":"2019","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12274-020-2904-8","article-title":"Nanotechnologies for Enhancing Cancer Immunotherapy","volume":"13","author":"Yang","year":"2020","journal-title":"Nano Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 Inhibitors as a Form of Cancer Immunotherapy: A Comprehensive Review of Registration Trials and Future Considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B10","doi-asserted-by":"crossref","DOI":"10.1146\/annurev.immunol.23.021704.115611","article-title":"The B7 Family Revisited","volume":"23","author":"Greenwald","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its Ligands in Tolerance and Immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/s0165-2478(02)00142-6","article-title":"Differential Expression of PD-L1 and PD-L2, Ligands for an Inhibitory Receptor PD-1, in the Cells of Lymphohematopoietic Tissues","volume":"84","author":"Ishida","year":"2002","journal-title":"Immunol Lett"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200324228","article-title":"Regulation of PD-1, Pd-L1, and PD-L2 Expression During Normal and Autoimmune Responses","volume":"33","author":"Liang","year":"2003","journal-title":"Eur J Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A Review of Cancer Immunotherapy Toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000282","article-title":"Combination Nivolumab\/Ipilimumab Immunotherapy For Melanoma With Subsequent Unexpected Cardiac Arrest: A Case Report and Review of Literature","volume":"42","author":"Khoury","year":"2019","journal-title":"J Immunother"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant Myocarditis With Combination Immune Checkpoint Blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3747\/co.26.4381","article-title":"Fatal Myocarditis and Rhabdomyositis in a Patient With Stage IV Melanoma Treated With Combined Ipilimumab and Nivolumab","volume":"26","author":"Saibil","year":"2019","journal-title":"Curr Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2019-0447-OA","article-title":"Histopathologic Characterization of Myocarditis Associated With Immune Checkpoint Inhibitor Therapy","volume":"144","author":"Sobol","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-20-0856","article-title":"A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention","volume":"11","author":"Wei","year":"2021","journal-title":"Cancer Discov"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.119.043171","article-title":"Heart-Specific Immune Responses in an Animal Model of Autoimmune-Related Myocarditis Mitigated by an Immunoproteasome Inhibitor and Genetic Ablation","volume":"141","author":"Bockstahler","year":"2020","journal-title":"Circulation"},{"key":"B22","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/circulationaha.118.034497","article-title":"Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e007405","DOI":"10.1161\/circheartfailure.120.007405","article-title":"Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document","volume":"13","author":"Ammirati","year":"2020","journal-title":"Circ Heart Fail"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht210","article-title":"Current State of Knowledge on Aetiology, Diagnosis, Management, and Therapy of Myocarditis: A Position Statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"34","author":"Caforio","year":"2013","journal-title":"Eur Heart J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s11936-017-0532-8","article-title":"Cardiovascular Complications Associated With Novel Cancer Immunotherapies","volume":"19","author":"Jain","year":"2017","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.119.044703","article-title":"Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.08.044","article-title":"Cardiac MR With Late Gadolinium Enhancement in Acute Myocarditis With\u00a0Preserved Systolic Function: Itamy Study","volume":"70","author":"Aquaro","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-00435-x","article-title":"Myocarditis and Inflammatory Cardiomyopathy: Current Evidence and Future Directions","volume":"18","author":"Tsch\u00f6pe","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-011-0176-x","article-title":"Systemic Therapy Options for Unresectable and Metastatic Chordomas","volume":"13","author":"Stacchiotti","year":"2011","journal-title":"Curr Oncol Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/BRS.0b013e31817e2d1e","article-title":"Identifying Mechanisms for Therapeutic Intervention in Chordoma: c-Met Oncoprotein","volume":"33","author":"Ostroumov","year":"2008","journal-title":"Spine (Phila Pa 1976)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11912-016-0543-8","article-title":"Immunotherapy as a Potential Treatment for Chordoma: A Review","volume":"18","author":"Patel","year":"2016","journal-title":"Curr Oncol Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(15)00145-3","article-title":"Myasthenia Gravis: Subgroup Classification and Therapeutic Strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(09)70063-8","article-title":"Autoimmune Myasthenia Gravis: Emerging Clinical and Biological Heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.682262\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T09:30:34Z","timestamp":1625736634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.682262\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":33,"alternative-id":["10.3389\/fimmu.2021.682262"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.682262","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,8]]},"article-number":"682262"}}